explore -WSS

explore

author：leisure time 2025-09-30 16:27:40 - browse：48691

Is Wegovy the future of cardiology? Can Novo Nordisk ever make enough of it? And will there ever be an Apple of pharma?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. In the wake of a massively important clinical trial of Novo Nordisk’s obesity drug Wegovy, our colleague Elaine Chen joins us to explain what we know and don’t know about data that could change the practice of medicine. Then, Mizuho Securities biotech strategist Jared Holz calls in to discuss whether explosive popularity of obesity treatments could help create the first trillion-dollar drug company.

For more on what we cover, here’s the news on the Wegovy study; here’s more on its implications; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Senators start work on Medicare physician payment reform

focus

entertainment

WSS

'Revelatory' study finds a smoking impact that remains after quitting

An inside look at PIPEs, biotech's buzzy new financing tool

FogPharma raises $145 million in rare Series E round

Kale crackers and hibiscus tea: My five days on a 'fasting diet'

Senators start work on Medicare physician payment reform

Vaccine advisory panel ACIP left half staffed by HHS

Wikipedia

explore

knowledge

The cancer drug shortage isn’t new — and neither are the solutions

Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

How to fix the rural physician shortage in the U.S.

Supreme Court strikes down use of affirmative action

An inside look at PIPEs, biotech's buzzy new financing tool

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

For Medicare Advantage, Democrats want stronger protections around AI

Tori Bowie and the unacceptable rates of Black maternal death

Covid isolation guidance eased by the CDC

focus

Private equity deals in Medicare Advantage declines

How to address the problem of discarded donor organs

BioAge raises $170M for combination therapy with Zepbound

The dental labor crisis is a moment of opportunity

Medicare Advantage proposed rates disappoint insurers

Readout LOUD podcast: How biotech is using artificial intelligence

hotspot

focus

entertainment

focus